Laval is the mothership site of Nexelis, a Q2 Solutions Company, with a history of success in developing vaccine technology for a broad array of infectious diseases. Download our factsheet to learn...
The outbreak of the SARS-CoV-2 virus caused a sudden shift in focus for the pharmaceutical industry. After the genetic sequence of the virus was released in early 2020, manufacturers across the globe...
This white paper highlights the challenges of emerging and re-emerging infectious diseases such as TB, MSSA/MRSA, and Ebola. At Q2 Solutions, we support infectious disease clinical trials with a...
